Aeglea BioTherapeutics Total Current Liabilities

Aeglea BioTherapeutics's total current liabilities stands at $85M as of March 2026. That compares with $71M in the prior-year period — up 20.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Aeglea BioTherapeutics reported $85M in total current liabilities versus $71M a year earlier — a 20.5% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $71M in the prior-year period — up 20.5% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Aeglea BioTherapeutics's total current liabilities evolved across reporting periods, while the comparison chart places AGLE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Aeglea BioTherapeutics's reading of $85M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.